A recent population-based study examined the prescribing and utilization of CT-P13 versus the reference infliximab in infliximab-naïve patients and found that discontinuation and switching were more common among patients who began therapy with the biosimilar.
Biosimilar infliximab, CT-P13, is approved and widely used in a number of regulatory territories. Among those territories is Turkey, where the product is used in treating diseases including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). A recent population-based study examined the prescribing and utilization of CT-P13 versus the reference infliximab in infliximab-naïve patients and found that discontinuation and switching were more common among patients who began therapy with the biosimilar.
The investigators used the Turkish Ministry of Health database, which includes pharmacy, inpatient, outpatient, and laboratory claims covering approximately 80% of the Turkish population, to identify adult patients with RA or IBD and at least 1 claim for an infliximab product after October 1, 2014, when biosimilar infliximab became available. The 779 patients with RA were followed for 12 months, and the 581 patients with IBD were followed for 6 months.
Among those with RA, 73.8% received the reference and 26.2% received the biosimilar. Mean age was not significantly different between groups, the use of noninfliximab biologics prior to infliximab was similar between groups, and most patients in both cohorts received anti-inflammatory and steroidal drugs. During the follow-up period, there was no significant difference in concomitant drug use.
Patients with RA receiving the reference had a higher average number of infusions (5.3) than those receiving the biosimilar (4.1) and a lower number of vials per infusion (4.9 vs 5.8, respectively). The mean number of days between infusions was shorter among those receiving the reference than the biosimilar (60 days vs 67 days, respectively). Mean time to discontinuation was significantly longer in the reference cohort (263 days) versus the biosimilar cohort (207 days). A total of 27.3% of the reference group discontinued treatment after dose 3, while 45.6% of the biosimilar cohort did the same. Fewer patients taking the reference (23.5%) than the biosimilar (35.8%) switched biologic treatments.
Among those with IBD, 87% received the reference and 13% received CT-P13. The mean age of the patients taking the reference was slightly lower (38 years) than that of those taking the biosimilar (41 years). A lower proportion of the patients in the reference cohort had a codiagnosis of ankylosing spondylitis, psoriasis, or RA (17.3%, 3.4%, and 11.3%, respectively) than in the biosimilar cohort (40.3%, 10.4%, and 19.5%, respectively). Concomitant medication patterns and procedures were similar between the groups.
Those receiving the reference had a higher mean number of infusions (6.5) than the biosimilar cohort (3.8), and a lower number of vials per infusion (4.2 vs 6.1). Mean time between infusions was shorter among those receiving the reference than the biosimilar (52 days vs 63 days, respectively). Mean time to discontinuation was longer in the reference cohort (288 days) than the biosimilar cohort (177 days). A total of 21.8% of the reference group discontinued treatment after dose 3, while 53.2% of the biosimilar cohort did so. Fewer patients taking the reference (14.1%) than the biosimilar (50.6%) switched biologic treatments.
The authors note that a key limitation of the study is a lack of information on reasons for discontinuing or switching. However, they write, “the results of this study demonstrate that medication utilization patterns for CT-P13 are not similar to those for [reference infliximab],” and further studies will be necessary to understand why patients receiving the biosimilar discontinued and switched treatment more often than their peers receiving the reference.
The study’s authors disclose connections with Janssen, maker of the reference infliximab.
Reference
Yazici Y, Xie L, Ogbomo A, et al. A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population. Biologics. 2018;12:97-106. doi: 10.2147/BTT.S172241.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.